92 related articles for article (PubMed ID: 9621809)
1. [Alendronate].
Sørensen HA; Hyldstrup L
Ugeskr Laeger; 1998 May; 160(22):3240-3. PubMed ID: 9621809
[No Abstract] [Full Text] [Related]
2. [Alendronate].
Lindberg M
Ugeskr Laeger; 1998 Oct; 160(44):6367-8. PubMed ID: 9810249
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
4. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
5. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates: safety and efficacy in the treatment and prevention of osteoporosis.
Greenspan SL; Harris ST; Bone H; Miller PD; Orwoll ES; Watts NB; Rosen CJ
Am Fam Physician; 2000 May; 61(9):2731-6. PubMed ID: 10821153
[TBL] [Abstract][Full Text] [Related]
7. [Diphosphonate therapy and osteonecrosis of the jaw].
Løkken P; Skoglund LA; Skjelbred P
Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
[No Abstract] [Full Text] [Related]
8. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Papapoulos SE
Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
[No Abstract] [Full Text] [Related]
9. [Osteoporosis therapy. Bisphosphonates compared].
MMW Fortschr Med; 2003 Mar; 145(13):60. PubMed ID: 15101545
[No Abstract] [Full Text] [Related]
10. [Osteoporosis medications. Bisphosphonates exceed the others].
MMW Fortschr Med; 2003 Oct; 145(42):66. PubMed ID: 14655453
[No Abstract] [Full Text] [Related]
11. [Treating with what? Therapy for how long?].
MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
[No Abstract] [Full Text] [Related]
12. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
13. [Osteoporosis and bisphosphonates].
Zuber MA
Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
[No Abstract] [Full Text] [Related]
14. [Postmenopausal osteoporosis. Bisphosphonates are not all equal].
MMW Fortschr Med; 2009 Mar; 151(11):46-7. PubMed ID: 19469206
[No Abstract] [Full Text] [Related]
15. Bisphosphonates and atrial fibrillation.
Prescrire Int; 2008 Aug; 17(96):161. PubMed ID: 19492493
[No Abstract] [Full Text] [Related]
16. Ten years of alendronate treatment for osteoporosis in postmenopausal women.
Ruggiero SL; Mehrotra B
N Engl J Med; 2004 Jul; 351(2):190-2; author reply 190-2. PubMed ID: 15250063
[No Abstract] [Full Text] [Related]
17. Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Skoglund K; Hjortdal O
Tidsskr Nor Laegeforen; 2015 Jan; 135(2):116-7. PubMed ID: 25625987
[No Abstract] [Full Text] [Related]
18. Osteonecrosis of the jaw and bisphosphonates.
Woo SB; Hande K; Richardson PG
N Engl J Med; 2005 Jul; 353(1):99-102; discussion 99-102. PubMed ID: 16003837
[No Abstract] [Full Text] [Related]
19. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
20. [Drugs for osteoporosis].
Hambro S
Tidsskr Nor Laegeforen; 1997 Jun; 117(17):2529. PubMed ID: 9265321
[No Abstract] [Full Text] [Related]
[Next] [New Search]
